Abstract

The introduction of preoperative concurrent chemoradiotherapy (CCRT) increases the rate of anal preservation and allows tumor downstaging for clinical stage T3/T4 or node-positive rectal cancer patients. However, there is no precise predictive tool to verify the presence of residual tumor apart from surgical resection. The gastrointestinal (GI) tract not only digests nutrients but also coordinates immune responses. As the outermost layer of the GI tract, mucus plays a key role in mediating the interaction between the digestive and immune systems, and aberrant mucus mesh formation may cause chemoresistance by impeding drug delivery. However, the correlations among digestion-related genes, mucin synthesis, and chemoresistance remain poorly understood. In the present study, we evaluated genes related to digestion (GO: 0007586) and identified cathepsin E (CTSE), which is involved in immune regulation, as the most significantly upregulated gene associated with CCRT resistance in rectal cancer in a public transcriptome dataset (GSE35452). We recovered 172 records of rectal cancer patients receiving CCRT followed by surgical resection from our biobank and evaluated the expression level of CTSE using immunohistochemistry. The results revealed that tumors with CTSE overexpression were significantly correlated with pre-CCRT and post-CCRT positive nodal status (both p < 0.001), advanced pre-CCRT and post-CCRT tumor status (p < 0.001 and p = 0.002), perineural invasion (p = 0.023), vascular invasion (p < 0.001), and a lesser degree of tumor regression (p = 0.003). At the univariate level, CTSE overexpression was an adverse prognostic factor for all three endpoints: disease-specific survival (DSS), metastasis-free survival (MeFS) (both p < 0.0001), and local recurrence-free survival (LRFS) (p = 0.0001). At the multivariate level, CTSE overexpression remained an independent prognostic factor for poor DSS, MeFS (both p = 0.005), and LRFS (p = 0.019). Through bioinformatics analysis, we speculated that CTSE overexpression may confer CCRT resistance by forming a defensive mucous barrier. Taken together, these results suggest that CTSE overexpression is related to CCRT resistance and inferior survival in rectal cancer patients, highlighting the potential predictive and prognostic value of CTSE expression.

Highlights

  • Originating in the colon or rectum, colorectal cancer (CRC) affects the lower digestive system and has increasingly become a substantial global burden

  • cathepsin E (CTSE) Is Identified as the Most Significant Differentially Expressed Gene Related to Digestion

  • We identified probes covering transcripts focusing on digestion

Read more

Summary

Introduction

Originating in the colon (large intestine) or rectum, colorectal cancer (CRC) affects the lower digestive system and has increasingly become a substantial global burden. The American Cancer Society (ACS) estimates that rectal cancer has accounted for approximately forty percent of the newly diagnosed CRC cases in 2021. It is noteworthy that Asia ranks first in terms of new CRC cases, CRC deaths, and the CRC 5-year prevalence rate [1]. In the early stage of rectal cancer, surgical resection is the standard intervention. T3/T4 or node-positive rectal cancer patients, the introduction of neoadjuvant concurrent chemoradiotherapy (CCRT) before surgery increases the rate of anal preservation and allows tumor downstaging. The assessment of the response to CCRT still relies on clinical procedures, including imaging techniques, random biopsy under colonoscopy, and digital rectal examination. There is no precise predictive tool to verify the presence of residual tumor apart from surgical resection. The identification of genetic biomarkers has benefitted from the advancement of precision medicine and can guide treatment modality selection more precisely (causing surgery to no longer be the only choice) and improve quality of life

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call